SCHEMBL874992

SCHEMBL874992

CC1(C)OB(c2ccc3nc[nH]c3c2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.45
PRKCI P41743 1/20 0.45
CYP3A4 P08684 1/20 0.44
NAMPT P43490 1/20 0.44
XDH P47989 1/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
RAD52 P43351 1/20 0.44
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
LPL P06858 4/20 0.40
LIPG Q9Y5X9 4/20 0.40
QPCT Q16769 3/20 0.40
PKM P14618 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
QPCTL Q9NXS2 1/20 0.40
EGFR P00533 2/20 0.39
HDAC6 Q9UBN7 1/20 0.38
SNCA P37840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29525463 1.00 MMP12 (0.45) MMP12PRKCICYP3A4NAMPTXDH
SCHEMBL2379179 0.88 LPL (0.40) MMP12KDM4EMAPTLPLLIPG
SCHEMBL12647374 0.87 LPL (0.52) MMP12KDM4EMAPTBRD4CREBBP
SCHEMBL20644622 0.82 KDM4E (0.47) KDM4EMAPTQPCT
SCHEMBL30050859 0.80 MMP12 (0.39) MMP12PRKCICYP3A4NAMPTXDH
SCHEMBL3263058 0.80 PRMT5 (0.40) LPLLIPGEGFR
SCHEMBL8212169 0.80 PARP1 (0.54) EGFR
SCHEMBL945212 0.77 BRD4 (0.42) BRD4LPLLIPG
SCHEMBL3225882 0.77 PRMT5 (0.40) LPLLIPGEGFR
SCHEMBL30016751 0.77 PARP1 (0.54) LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 US disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 EP disclosed
WO-2025087274-A1 AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE 浙江海正药业股份有限公司 2025-05-01 WO disclosed
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 WO disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
CN-114901664-B Pyridone compounds and uses thereof 南京再明医药有限公司 2024-07-02 CN disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
WO-2022268176-A1 STEROID COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 江苏先声药业有限公司 2022-12-29 WO disclosed
US-20150126366-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES CORTEVA AGRISCIENCE LLC 2015-05-07 US disclosed
US-20150038510-A1 CINNOLINE DERIVATIVES TAKEDA CALIFORNIA, INC. 2015-02-05 US disclosed
US-20140274695-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2014-09-18 US disclosed
US-20140107073-A1 GDF-8 Inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2014-04-17 US disclosed
US-20140107073-A1 GDF-8 Inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2014-04-17 US disclosed
US-8569281-B2 Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2013-10-29 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
EP-2619201-A1 PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 Medical Research Council Technology (GB) 2013-07-31 EP disclosed
US-20120295883-A1 COMPOUNDS GENENTECH, INC. (US) 2012-11-22 US disclosed
WO-2012038743-A1 PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107073-A1 GDF-8 Inhibitors MSTN, MYOF, CXCL8 MMP12 884/4885PRKCI 1549/4885CYP3A4 4688/4885
US-20120295883-A1 COMPOUNDS ABCC5, PRNP, PC MMP12 4375/4885PRKCI 2218/4885CYP3A4 56/4885
US-20140274695-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-amino-2-(HETEROCYCLIC)pyrimidine-4-carboxylates AND THEIR USE AS HERBICIDES DDT, DDC, P2RX6 MMP12 4612/4885PRKCI 4183/4885CYP3A4 200/4885
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 MMP12 1715/4885PRKCI 1822/4885CYP3A4 1957/4885
US-20150126366-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DDT, DDC, P2RX6 MMP12 4612/4885PRKCI 4183/4885CYP3A4 200/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT MMP12 1842/4885PRKCI 1710/4885CYP3A4 4294/4885
US-20150038510-A1 CINNOLINE DERIVATIVES BTK, LYN, ABL1 MMP12 4346/4885PRKCI 403/4885CYP3A4 1464/4885
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NADK, NEK1 MMP12 3603/4885PRKCI 2163/4885CYP3A4 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.